Key clinical point: Venetoclax with a hypomethylating agent was safe and effective as first-line therapy for older adults with AML who were ineligible for standard induction chemotherapy.

Major finding: At a median time of study of 8.9 months, the overall response rate among all treated patients was 68%.

Study details: Follow-up of a phase 1b dose-escalation and expansion cohort of 145 patients aged 65 years and older with treatment-naive AML.

Disclosures: The trial was supported by AbbVie and Genentech. Dr. DiNardo and multiple coauthors disclosed relationships with AbbVie, Genentech, and other companies.

Read the article.